Raloxifene is an oral selective estrogen receptor modulator which is used in the prevention of osteoporosis in postmenopausal women. There has been some evidence that raloxifene can reduce the incidence of breast cancer, but this has yet to be proven in a clinical setting. Raloxifene is produced by Eli Lilly Pharmaceuticals and is sold under the brand name Evista.
SERMs mimic estrogen in some tissues and have anti-estrogen activity in others. Other SERMs, such as Pfizer's lasofoxifene and Wyeth's bazedoxifene are in the late stages of clinical development.